Pulmonx Corp (LUNG) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Pulmonx reported revenue of $90.5M, up 8.0% from $83.8M the year before. Net income was -$54.0M (a -59.7% net margin), or -$1.33 per diluted share. Gross margin was 74.2% and operating margin was -59.3%. Operating activities generated -$32.4M of cash, leaving -$32.9M of free cash flow. At fiscal year end, Pulmonx held $129.3M in total assets against $75.2M in total liabilities, including $69.8M of cash and equivalents.
Open the full interactive Pulmonx financials → Quarterly statements, key ratios, valuation history and price charts.
Pulmonx Key Stats
| Share Price | $1.76 |
|---|---|
| Market Cap | $74.7M |
| Revenue YoY Growth | +8.0% |
| 52-Week Range | $1.17 – $2.60 |
| Shares Outstanding | 42.5 million (basic, 2026 Q2) |
Pulmonx Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $32.7M | $48.4M | $53.7M | $68.7M | $83.8M | $90.5M |
| Cost of Goods Sold | $11.5M | $12.8M | $13.8M | $17.9M | $21.8M | $23.4M |
| Gross Profit | $21.2M | $35.6M | $39.9M | $50.8M | $62.0M | $67.1M |
| Operating Income | -$32.3M | -$47.3M | -$58.6M | -$61.9M | -$57.7M | -$53.7M |
| Pre-Tax Income | -$32.0M | -$48.3M | -$58.6M | -$60.3M | -$55.9M | -$53.4M |
| Income Tax | $213,000 | $343,000 | $353,000 | $571,000 | $500,000 | $626,000 |
| Net Income | -$32.2M | -$48.7M | -$58.9M | -$60.8M | -$56.4M | -$54.0M |
| Diluted EPS | -$3.16 | -$1.35 | -$1.59 | -$1.60 | -$1.44 | -$1.33 |
Pulmonx Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $21.5M | $22.6M | $20.6M | $22.8M |
| Net Income | -$14.0M | -$10.4M | -$13.7M | -$10.1M |
| Diluted EPS | -$0.34 | -$0.26 | -$0.33 | -$0.24 |
Pulmonx Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $231.6M | $148.5M | $101.7M | $83.5M | $70.9M | $69.8M |
| Current Assets | $250.0M | $208.0M | $169.0M | $150.4M | $136.2M | $101.7M |
| Total Assets | $263.7M | $235.2M | $193.7M | $177.8M | $162.8M | $129.3M |
| Current Liabilities | $12.5M | $17.6M | $18.5M | $23.2M | $24.4M | $20.1M |
| Total Long-Term Debt | $17.4M | $17.4M | $17.3M | $37.2M | $37.2M | $37.1M |
| Total Liabilities | $37.6M | $41.9M | $39.7M | $59.5M | $77.0M | $75.2M |
| Shareholders' Equity | $226.1M | $193.2M | $154.0M | $118.3M | $85.8M | $54.1M |
Pulmonx Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$30.6M | -$41.4M | -$45.1M | -$37.6M | -$31.5M | -$32.4M |
| Cash From Investing | $12.7M | -$46.3M | -$4.2M | -$2.0M | $17.5M | $30.5M |
| Cash From Financing | $234.8M | $4.5M | $2.4M | $21.4M | $1.4M | $833,000 |
| Free Cash Flow | -$31.5M | -$45.1M | -$46.4M | -$38.4M | -$32.9M | -$32.9M |
Figures from Pulmonx's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Pulmonx financials page for every line item.
Pulmonx Company Profile
| Ticker | LUNG |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Redwood City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001127537 |
Frequently Asked Questions
What was Pulmonx's revenue in fiscal 2025?
Pulmonx (LUNG) reported revenue of $90.5M for fiscal 2025.
What is Pulmonx's annual revenue history?
Pulmonx's annual revenue by fiscal year: 2020: $32.7M; 2021: $48.4M; 2022: $53.7M; 2023: $68.7M; 2024: $83.8M; 2025: $90.5M.
What was Pulmonx's net income in fiscal 2025?
Pulmonx reported net income of -$54.0M for fiscal 2025.
What was Pulmonx's earnings per share (EPS) in fiscal 2025?
Pulmonx's diluted EPS was -$1.33 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Pulmonx generate in fiscal 2025?
Pulmonx generated -$32.9M of free cash flow in fiscal 2025.
What was Pulmonx's revenue last quarter?
In its most recent reported quarter (2026 Q2), Pulmonx reported revenue of $22.8M.
How much debt does Pulmonx have?
Pulmonx reported $37.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Pulmonx are outstanding?
Pulmonx reported a weighted average of 42.5 million basic shares outstanding in 2026 Q2.
What is Pulmonx's market cap?
Based on its latest closing price, Pulmonx (LUNG) has a market capitalization of about $74.7M.
When does Pulmonx's fiscal year end?
Pulmonx's fiscal year end, as registered with the SEC, is December 31.
Where is Pulmonx headquartered?
Pulmonx lists its business address in Redwood City, California in its SEC filings.